Arjuna’s turmeric extract granted ‘No Questions’ letter from the FDA

By Gary Scattergood

- Last updated on GMT

BCM-95 was granted self-affirmed GRAS status in 2016. ©iStock
BCM-95 was granted self-affirmed GRAS status in 2016. ©iStock
Arjuna Naturals Extracts’ BCM-95 turmeric extract has been granted a ‘No Questions’ response letter from the US Food and Drug Administration (FDA). 

The Indian firm says this confirms the safety of BCM-95 by the US authority and “helps position the ingredient as an all-natural, clean and trusted brand of the powerful curcumin antioxidant.”

BCM-95 is a proprietary combination of curcuminoids and essential oil of turmeric-ar-turmerone and has been the subject of 33 clinical studies.

In 2016, BCM-95 was granted self-affirmed GRAS status (Generally Recognized as Safe) by an expert panel of scientists for use in medical foods at a dose of 500 mg, twice a day.

“The FDA’s latest positive response is a testimony to our unwavering commitment to ensure maximum safety and quality products,”​ said Benny Antony, joint managing director for Arjuna.

The company recently completed construction of a new facility in Coimbatore, India, to produce the product.

The project was designed to triple the company’s curcumin capacity​ and maximise its efficiency and output, and at the same time reduce waste.

Related topics Suppliers South Asia Botanicals

Related news

Follow us


View more


Nutra Champions Podcast

Nutra Champions Podcast